What are the indications for Paxlovid (nirmatrelvir + ritonavir) in treating COVID‑19?

Indications for Paxlovid (Nirmatrelvir/Ritonavir)

Paxlovid is indicated for adults with confirmed mild-to-moderate COVID-19 who are at high risk for progression to severe disease, initiated within 5 days of symptom onset. 1, 2

FDA-Approved Indication

• Paxlovid is FDA-approved for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19, including hospitalization or death. 1, 2
• Treatment must be initiated as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset. 1, 2
• Paxlovid is NOT approved for pre-exposure or post-exposure prophylaxis for prevention of COVID-19. 1, 2

High-Risk Criteria for Treatment

The American College of Physicians and WHO define high-risk patients as those with one or more of the following: 3, 4, 5

• Age ≥65 years (independent risk factor) 3, 4
• Unvaccinated or incompletely vaccinated status 3, 4
• Immunosuppression (including transplant recipients, active cancer treatment, immunomodulatory therapy) 3, 4, 5
• Multiple comorbidities (≥3 conditions such as cardiovascular disease, diabetes, chronic kidney disease, chronic lung disease) 3, 4, 5
• Hematological disease 3, 5
• Radiographic evidence of pneumonia (such as patchy bilateral opacities) 3, 4

Critical Timing Window

• Delaying treatment beyond 5 days of symptom onset significantly reduces effectiveness. 3, 4, 5
• Initiate treatment as soon as possible after positive COVID-19 test, ideally within the first 1-2 days of symptom onset for maximum benefit. 4, 1, 2

Who Should NOT Receive Paxlovid

The WHO and American College of Physicians recommend against using Paxlovid in low-risk patients with non-severe COVID-19, as benefits are trivial and do not justify the risks of drug interactions and adverse effects. 3

Absolute Contraindications: 1, 2

• History of clinically significant hypersensitivity to nirmatrelvir or ritonavir
• Co-administration with drugs highly dependent on CYP3A for clearance where elevated concentrations cause serious/life-threatening reactions
• Co-administration with potent CYP3A inducers (risk of treatment failure and resistance)

Relative Contraindications/Special Populations:

• Severe renal impairment (eGFR <30 mL/min): Requires dose modification; on hemodialysis days, administer after dialysis 4, 2
• Severe hepatic impairment (Child-Pugh Class C): Not recommended 4, 1, 2
• Pregnancy and breastfeeding: May be considered with shared decision-making about risks versus benefits 3

Moderate-Risk Patients

• The WHO suggests (conditional recommendation) using Paxlovid in moderate-risk patients with non-severe COVID-19, though absolute benefits are smaller compared to high-risk patients. 3
• This represents a weaker recommendation due to less robust evidence of benefit in this population. 3

Critical Pre-Treatment Requirement

A comprehensive medication review using a drug interaction checker (such as the Liverpool COVID-19 Drug Interaction Tool) is MANDATORY before prescribing Paxlovid. 3, 4, 5

• Ritonavir is a potent CYP3A4 inhibitor that can cause potentially life-threatening drug interactions. 3, 4, 1, 2
• Common problematic interactions include certain antiarrhythmics, anticoagulants, statins, immunosuppressants, and sedatives. 4
• Some medications may require dose adjustment, temporary discontinuation, or additional monitoring during the 5-day treatment course. 3, 4

Clinical Benefits Supporting These Indications

Real-world effectiveness data demonstrates: 3, 6

• 39% relative risk reduction in hospitalization 3, 6
• 61% relative risk reduction in death 3, 6
• Benefits observed in both vaccinated and unvaccinated patients 3, 6
• Efficacy maintained against Omicron subvariants through August 2023 3
• Absolute risk reduction for hospitalization is greatest among patients aged ≥65 years 6

Alternative Therapies When Paxlovid Is Contraindicated

• Remdesivir (3-day IV course): Preferred alternative for patients with problematic ritonavir drug interactions, pregnancy, or severe renal impairment 3, 4, 5
• Molnupiravir: Less effective oral alternative when Paxlovid is unavailable or contraindicated; Paxlovid demonstrates superior reduction in hospitalization 3, 4, 5

Common Pitfall to Avoid

Do not prescribe Paxlovid to all COVID-19 positive patients simply because they test positive early. Low-risk patients (young, vaccinated, no comorbidities) derive minimal benefit and face unnecessary exposure to drug interaction risks and adverse effects. 3 The indication is specifically for high-risk patients, not all patients with early COVID-19.